BioAge - BIOA Total Company Value-to-Revenue Ratio

Public company logo of bioagelabs.com (BIOA)

BioAge Labs, Inc. (BIOA) is a longevity innovator with a robust analytical foundation that has earned expert recognition. The EV/Sales trajectory illustrates the current market valuation, where -7494.19 indicates the level of this metric. Steady demand for metabolic disorder treatments creates long-term growth potential, while the recruitment of leading data scientists following the IPO ensures the development of cutting-edge R&D competencies.

BIOA BioAge Labs, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

BioAge Labs, Inc - analytical breakdowns and key metrics (BIOA)

Initial company analysis:BIOA, BioAge Labs, Inc.
Flagship merchandise of BioAge Labs Inc.

The investment attractiveness of BioAge Labs, Inc. (BIOA) is driven by the potential of its therapies for metabolic disorders and aging. This metric compares the total enterprise value, including net debt, against the volume of generated sales. By analyzing the company's EV/Sales valuation, an investor can determine the market value of one dollar of revenue regardless of leverage. In the biopharmaceutical sector, this indicator reflects expectations for future insurance reimbursements. This chart confirms the effective capitalization of intellectual assets.

Competitor analysis for BioAge Labs, Inc.

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)